Drug profile

The FDA adverse-event record for Prednisolone; Trimeprazine Tartrate

817 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Prednisolone; Trimeprazine Tartrate. See the species affected, top reactions, and outcomes below.

817
adverse-event reports
7.8%
death-coded share
Dog
most-reported species
148
Lack of efficacy - NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
817
Total Reports
64
Deaths Reported
7.8%
Death Rate

Active Ingredients

Prednisolone; Trimeprazine Tartrate

Administration Routes

OralUnknownOphthalmicSubcutaneous

Species Affected

Dog 786
Unknown 25
Cat 4
Human 2

Most Affected Breeds

Retriever - Labrador 79
Shih Tzu 59
Terrier - Yorkshire 42
Chihuahua 33
Unknown 27
Dog (unknown) 27
Retriever - Golden 26
Boxer (German Boxer) 23
Maltese 23
Terrier - Jack Russell 21

Most Reported Reactions

Lack of efficacy - NOS 148
Lethargy (see also Central nervous system depression in 'Neurological') 102
INEFFECTIVE, LOSS OF EFFECT 100
Vomiting 97
Elevated serum alkaline phosphatase (SAP) 83
Other abnormal test result NOS 75
INEFFECTIVE, ATOPY CONTROL 71
Polydipsia 64
Polyuria 58
Diarrhoea 53
Anorexia 53
Elevated alanine aminotransferase (ALT) 44

Outcome Breakdown

Ongoing
496 (62.6%)
Outcome Unknown
119 (15.0%)
Recovered/Normal
112 (14.1%)
Euthanized
35 (4.4%)
Died
29 (3.7%)
Recovered with Sequela
1 (0.1%)

Prednisolone; Trimeprazine Tartrate Adverse Event Insights

817 reports name Prednisolone; Trimeprazine Tartrate; 64 recorded a death outcome (7.8% of reported events, not a population-level mortality rate). Active ingredient: Prednisolone; Trimeprazine Tartrate. Administration routes: Oral, Unknown, Ophthalmic, Subcutaneous.

By species: Dog (786 reports), Unknown (25 reports), Cat (4 reports). By breed: Retriever - Labrador (79), Shih Tzu (59), Terrier - Yorkshire (42).

Leading clinical signs: Lack of efficacy - NOS (148), Lethargy (see also Central nervous system depression in 'Neurological') (102), INEFFECTIVE, LOSS OF EFFECT (100), Vomiting (97). Outcome, 792 coded reports: Ongoing leads at 62.6%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.